This was the stock's second consecutive day of losses.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

Bio-Techne Corporation TECH recently announced the launch of a new line of designer proteins engineered using advanced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

In a report released on January 10, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a ...

IL-2 Heat Stable Agonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor ...

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...